BRAIN and Autodisplay Biotech cooperate
Joint development of innovative screening systems on the basis of cellularly exposed human protein systems
BRAIN cooperates with Autodisplay Biotech, a technological leader in bacterial surface expression of proteins, a move which perfectly complements BRAIN's own screening systems and thus strategically expands the company's technology platform.
For BRAIN the collaboration announced today represents another important milestone in its corporate strategy to intensify co-operation with technology companies in order to drive forward the research and development of novel cosmetic actives.
For Autodisplay Biotech co-operating with BRAIN paves the way for a consistent further development of its own technology. The use of the surface expression technology and its direct application constitutes a tailor-made solution for the identification of bioactives within the project.
"This strategic co-operation helps us tap into an immense potential for synergy, which will make those human target molecules in particular accessible to an intensive BioActives screening which would not be accessible using traditional technologies," explains Dr Jürgen Eck, Chief Scientific Officer of BRAIN AG. "Screenings for new modes of action, a core competency of white biotechnology, have been at the top of BRAIN's agenda for many years as they offer an immense potential for growth. This is why we are looking very much forward to intensively using and jointly advancing the synergies resulting from the co-operation between the two companies."
About Autodisplay Biotech
Autodisplay Biotech GmbH are technology leaders in bacterial surface expression. Using this technology, anything from simple peptides to complex proteins can be presented on the surfaces of bacteria and thus may be used to identify innovative products in the biocatalysis and bioanalytics fields of the chemicals and pharmaceuticals industry. Ever since its foundation as a spin-off from Düsseldorf's Heinrich Heine University in 2008, Autodisplay Biotech's founders Prof. Dr. Jose, Dr. Ruth Maas and Dr. Gunter Festel and their six employees have focussed on the consistent further development of their proprietary technology. This will permit the company to offer intelligent solution-oriented screening and production systems for the bio-based industry of tomorrow.
BRAIN AG is an industrial "white" biotech company which discovers and develops novel bioactive natural compounds and proprietary enzymes for its partners and customers in the chemical and pharmaceutical industries, as well as the food and cosmetics industries. With its unique approach to the discovery and production of new biological compounds and biocatalysts, the company achieves creative solutions by harnessing nature's untapped biodiversity. Its success is built on its proprietary BioArchive comprising millions of genes, proteins and metabolic pathways from microbial isolates and metagenome libraries. Since its foundation in 1993, BRAIN has entered into over 70 strategic collaborations with nearly all the relevant companies within the chemical industry as e.g. BASF, Ciba, Clariant, Evonik Degussa, DSM, Genencor, Henkel, Nutrinova, RWE, Sandoz, Schering, Südzucker and Symrise, to name but a few. Currently, BRAIN employs 99 highly skilled people.
For their groundbreaking industrial biotechnology activities for a sustainable "biologisation of the chemical industry" using nature's toolbox for industrial processes, BRAIN with its CEO Dr. Holger Zinke received the "Deutschen Umweltpreis 2008" of the "Deutsche Bundesstiftung Umwelt", DBU.